Skip to content
RDL Network logo
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial — Anthony B. El-Khoueiry (2017) | RDL Network